ABSTRACT
Increasing evidence that microRNAs (miRNAs) play important roles in the immune response against infectious agents suggests that miRNA might be exploitable as signatures of exposure to specific infectious agents. In order to identify potential early miRNA biomarkers of bacterial infections, human peripheral blood mononuclear cells (hPBMCs) were exposed to two select agents, Burkholderia pseudomallei K96243 and Francisella tularensis SHU S4, as well as to the nonpathogenic control Escherichia coli DH5α. RNA samples were harvested at three early time points, 30, 60, and 120 minutes postexposure, then sequenced. RNAseq analyses identified 87 miRNAs to be differentially expressed (DE) in a linear fashion. Of these, 31 miRNAs were tested using the miScript miRNA qPCR assay. Through RNAseq identification and qPCR validation, we identified differentially expressed miRNA species that may be involved in the early response to bacterial infections. Based upon its upregulation at early time points postexposure in two different individuals, hsa-mir-30c-5p is a miRNA species that could be studied further as a potential biomarker for exposure to these gram-negative intracellular pathogens. Gene ontology functional analyses demonstrated that programmed cell death is the first ranking biological process associated with miRNAs that are upregulated in F. tularensis-exposed hPBMCs.
ABSTRACT
Subunit formulations are regarded as the safest type of vaccine, but they often contain a protein-based antigen that can result in significant challenges, such as preserving antigenicity during formulation and administration. Many studies have demonstrated that encapsulation of protein antigens in polymeric microparticles (MPs) via emulsion techniques results in total IgG antibody titers comparable to alum formulations, however, the antibodies themselves are non-neutralizing. To address this issue, a coaxial electrohydrodynamic spraying (electrospray) technique is used to formulate a microparticulate-based subunit anthrax vaccine under conditions that minimize recombinant protective antigen (rPA) exposure to harsh solvents and high shear stress. rPA and the adjuvant resiquimod are encapsulated either in separate or the same acetalated dextran MPs. Using a murine model, the electrospray formulations lead to higher IgG2a subtype titers as well as comparable total IgG antibody titers and toxin neutralization relative to the FDA-approved vaccine (BioThrax). BioThrax provides no protection against a lethal inhalational challenge of the highly virulent Ames Bacillus anthracis anthrax strain, whereas 50% of the mice vaccinated with separately encapsulated electrospray MPs survive. Overall, this study demonstrates the potential use of electrospray for encapsulating protein antigens in polymeric MPs.
Subject(s)
Antibodies, Neutralizing/immunology , Bacillus anthracis/immunology , Bacterial Toxins/immunology , Dextrans/chemistry , Dextrans/immunology , Vaccines/chemistry , Vaccines/immunology , Animals , Anthrax/immunology , Anthrax Vaccines/immunology , Antigens, Bacterial/immunology , Chemistry, Pharmaceutical/methods , Female , Immunoglobulin G/immunology , Mice , Mice, Inbred BALB C , Polymers/chemistryABSTRACT
Burkholderia mallei and Burkholderia pseudomallei are potentially lethal pathogens categorized as biothreat agents due, in part, to their ability to be disseminated via aerosol. There are no protective vaccines against these pathogens and treatment options are limited and cumbersome. Since disease severity is greatest when these agents are inhaled, efforts to develop pre- or post-exposure prophylaxis focus largely on inhalation models of infection. Here, we demonstrate a non-invasive and technically simple method for affecting the inhalational challenge of BALB/c mice with B. pseudomallei and B. mallei. In this model, two investigators utilized common laboratory tools such as forceps and a micropipette to conduct and characterize an effective and reproducible inhalational challenge of BALB/c mice with B. mallei and B. pseudomallei. Challenge by oropharyngeal aspiration resulted in acute disease. Additionally, 50% endpoints for B. pseudomallei K96243 and B. mallei ATCC 23344 were nearly identical to published aerosol challenge methods. Furthermore, the pathogens disseminated to all major organs typically targeted by these agents where they proliferated. The pro-inflammatory cytokine production in the proximal and peripheral fluids demonstrated a rapid and robust immune response comparable to previously described murine and human studies. These observations demonstrate that OA is a viable alternative to aerosol exposure.
Subject(s)
Bacterial Infections/pathology , Burkholderia mallei/pathogenicity , Burkholderia pseudomallei/pathogenicity , Immunity, Innate , Acute Disease , Animals , Bacterial Infections/immunology , Bacterial Infections/transmission , Burkholderia mallei/immunology , Burkholderia pseudomallei/immunology , Disease Models, Animal , Female , Host-Pathogen Interactions/immunology , Humans , Mice , Mice, Inbred BALB C , Post-Exposure ProphylaxisABSTRACT
Vaccines have evolved for hundreds of years, but all utilize the premise that safely pre-exposing the host to some component of a pathogen allows for enhanced immune recognition, and potential protection from disease, upon encountering the pathogen at a later date. Early vaccination strategies used inactivated or attenuated vaccines, many of which contained toxins and other components that resulted in reactogenicity or risk of reversion to virulence. DNA vaccines supplant many of the issues associated with inactivated or attenuated vaccines, but these vaccines tend to provide weak immunological responses, particularly in primates. DNA Electroporation may prove to be the "missing link" in the evolution of DNA vaccines allowing for enhanced immune responses from DNA vaccination in humans thereby resulting in protection from disease post-pathogen exposure.
Subject(s)
Electroporation/methods , Vaccines, DNA/metabolism , Animals , DNA/immunology , DNA/metabolism , Epidermis , Humans , Immunization , Vaccines, DNA/immunologyABSTRACT
Effective multi-agent/multivalent vaccines that confer protection against more than one disease are highly desirable to the patient and to health-care professionals. Electroporation of DNA vaccines, whereby tissues injected with DNA are subjected to localized electrical currents, is an ideal platform technology that achieves protective immune responses to multivalent vaccination. Here, we describe an electroporation-based immunization technique capable of administering a cocktail of DNA vaccinations in vivo. Immune response measurements, including protection from pathogen challenge and induction of antigen-specific antibody responses and cell-mediated immune responses, are also discussed.
Subject(s)
Electroporation/methods , Vaccines, DNA/immunology , Vaccines, DNA/metabolism , Animals , Electrodes , Electroporation/instrumentation , Female , Mice , Plasmids/geneticsABSTRACT
Electroporation of DNA vaccines represents a platform technology well positioned for the development of multivalent biodefense vaccines. To evaluate this hypothesis, three vaccine constructs were produced using codon-optimized genes encoding Bacillus anthracis Protective Antigen (PA), and the Yersinia pestis genes LcrV and F1, cloned into pVAX1. A/J mice were immunized on a prime-boost schedule with these constructs using the electroporation-based TriGrid Delivery System. Immunization with the individual pDNA vaccines elicited higher levels of antigen-specific IgG than when used in combination. DNA vaccine effectiveness was proven, the pVAX-PA titers were toxin neutralizing and fully protective against a lethal B. anthracis spore challenge when administered alone or co-formulated with the plague pDNA vaccines. LcrV and F1 pVAX vaccines against plague were synergistic, resulting in 100% survival, but less protective individually and when co-formulated with pVAX-PA. These DNA vaccine responses were Th1/Th2 balanced with high levels of IFN-γ and IL-4 in splenocyte recall assays, contrary to complimentary protein Alum vaccinations displaying a Th2 bias with increased IL-4 and low levels of IFN-γ. These results demonstrate the feasibility of electroporation to deliver and maintain the overall efficacy of an anthrax-plague DNA vaccine cocktail whose individual components have qualitative immunological differences when combined.
Subject(s)
Anthrax Vaccines/administration & dosage , Electroporation , Immunization/methods , Plague Vaccine/administration & dosage , Vaccines, DNA/administration & dosage , Adjuvants, Immunologic/administration & dosage , Alum Compounds/administration & dosage , Animals , Anthrax/prevention & control , Anthrax Vaccines/immunology , Antibodies, Bacterial/blood , Antibody Formation , Feasibility Studies , Female , Immunoglobulin G/blood , Interferon-gamma/immunology , Interleukin-4/immunology , Mice , Plague/prevention & control , Plague Vaccine/immunology , Plasmids/administration & dosage , Plasmids/immunology , Spleen/immunology , Th1-Th2 Balance , Vaccines, Combined/administration & dosage , Vaccines, DNA/immunologyABSTRACT
The efficacy of multi-agent DNA vaccines consisting of a truncated gene encoding Bacillus anthracis lethal factor (LFn) fused to either Yersinia pestis V antigen (V) or Y . pestis F1 was evaluated. A/J mice were immunized by gene gun and developed predominantly IgG1 responses that were fully protective against a lethal aerosolized B. anthracis spore challenge but required the presence of an additional DNA vaccine expressing anthrax protective antigen to boost survival against aerosolized Y. pestis.
Subject(s)
Anthrax Vaccines/immunology , Anthrax/prevention & control , Plague Vaccine/immunology , Plague/prevention & control , Animals , Anthrax/immunology , Anthrax/mortality , Anthrax Vaccines/administration & dosage , Antibodies, Bacterial/blood , Antibodies, Bacterial/immunology , Antigens, Bacterial/genetics , Antigens, Bacterial/immunology , Bacillus anthracis/immunology , Bacillus anthracis/pathogenicity , Bacterial Proteins/genetics , Bacterial Proteins/immunology , Bacterial Toxins/genetics , Bacterial Toxins/immunology , Biolistics , Immunization , Immunoglobulin G/blood , Immunoglobulin G/immunology , Mice , Plague/immunology , Plague/mortality , Plague Vaccine/administration & dosage , Pore Forming Cytotoxic Proteins/genetics , Pore Forming Cytotoxic Proteins/immunology , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Spores, Bacterial/immunology , Spores, Bacterial/pathogenicity , Survival Rate , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/immunology , Yersinia pestis/immunologyABSTRACT
Rapid presymptomatic diagnosis of Bacillus anthracis at early stages of infection plays a crucial role in prompt medical intervention to prevent rapid disease progression and accumulation of lethal levels of toxin. To detect low levels of the anthrax protective antigen (PA) exotoxin in biological fluids, we have developed a metal-enhanced fluorescence (MEF)-PA assay using a combination of the MEF effect and microwave-accelerated PA protein surface absorption. The assay is based on a modified version of our "rapid catch and signal" (RCS) technology previously designed for the ultra-fast and sensitive analysis of genomic DNA sequences. Technologically, the proposed MEF-PA assay uses standard 96-well plastic plates modified with silver island films (SiFs) grown within the wells. It is shown that the fluorescent probe, covalently attached to the secondary antibody, plays a crucial role of indicating complex formation (i.e., shows a strong MEF response to the recognition event). Microwave irradiation rapidly accelerates PA deposition onto the surface ("rapid catch"), significantly speeding up the MEF-PA assay and resulting in a total assay run time of less than 40 min with an analytical sensitivity of less than 1 pg/ml PA.
Subject(s)
Antigens, Bacterial/analysis , Bacterial Toxins/analysis , Fluorescence , Microwaves , Silver/chemistry , Antigens, Bacterial/chemistry , Bacillus anthracis/immunology , Bacillus anthracis/isolation & purification , Bacterial Toxins/chemistry , Metals/chemistryABSTRACT
Bacillus cereus G9241 was isolated from a welder with a pulmonary anthrax-like illness. The organism contains two megaplasmids, pBCXO1 and pBC218. These plasmids are analogous to the Bacillus anthracis Ames plasmids pXO1 and pXO2 that encode anthrax toxins and capsule, respectively. Here we evaluated the virulence of B. cereus G9241 as well as the contributions of pBCXO1 and pBC218 to virulence. B. cereus G9241 was avirulent in New Zealand rabbits after subcutaneous inoculation and attenuated 100-fold compared to the published 50% lethal dose (LD(50)) values for B. anthracis Ames after aerosol inoculation. A/J and C57BL/6J mice were comparably susceptible to B. cereus G9241 by both subcutaneous and intranasal routes of infection. However, the LD(50)s for B. cereus G9241 in both mouse strains were markedly higher than those reported for B. anthracis Ames and more like those of the toxigenic but nonencapsulated B. anthracis Sterne. Furthermore, B. cereus G9241 spores could germinate and disseminate after intranasal inoculation into A/J mice, as indicated by the presence of vegetative cells in the spleen and blood of animals 48 h after infection. Lastly, B. cereus G9241 derivatives cured of one or both megaplasmids were highly attenuated in A/J mice. We conclude that the presence of the toxin- and capsule-encoding plasmids pBCXO1 and pBC218 in B. cereus G9241 alone is insufficient to render the strain as virulent as B. anthracis Ames. However, like B. anthracis, full virulence of B. cereus G9241 for mice requires the presence of both plasmids.
Subject(s)
Anthrax/pathology , Antigens, Bacterial/biosynthesis , Bacillus anthracis/metabolism , Bacillus anthracis/pathogenicity , Bacillus cereus/metabolism , Bacillus cereus/pathogenicity , Bacterial Capsules/biosynthesis , Bacterial Toxins/biosynthesis , Administration, Inhalation , Aerosols/administration & dosage , Animals , Anthrax/microbiology , Antigens, Bacterial/genetics , Bacillus anthracis/genetics , Bacillus cereus/genetics , Bacterial Capsules/genetics , Bacterial Toxins/genetics , Disease Models, Animal , Female , Lethal Dose 50 , Mice , Mice, Inbred A , Mice, Inbred C57BL , Plasmids/analysis , Rabbits , Rodent Diseases/microbiology , Rodent Diseases/pathology , Virulence , Virulence Factors/biosynthesis , Virulence Factors/geneticsABSTRACT
Toll-like receptor (TLR) agonists induce potent innate immune responses and can be used in the development of novel vaccine adjuvants. However, access to TLRs can be challenging as exemplified by TLR 7, which is located intracellularly in endosomal compartments. To increase recognition and subsequent stimulatory effects of TLR 7, imiquimod was encapsulated in acetalated dextran (Ac-DEX) microparticles. Ac-DEX, a water-insoluble and biocompatible polymer, is relatively stable at pH 7.4, but degrades rapidly under acidic conditions, such as those found in lysosomal vesicles. To determine the immunostimulatory capacity of encapsulated imiquimod, we compared the efficacy of free versus encapsulated imiquimod in activating RAW 264.7 macrophages, MH-S macrophages, and bone marrow derived dendritic cells. Encapsulated imiquimod significantly increased IL-1 beta, IL-6, and TNF-alpha cytokine expression in macrophages relative to the free drug. Furthermore, significant increases were observed in classic macrophage activation markers (iNOS, PD1-L1, and NO) after treatment with encapsulated imiquimod over the free drug. Also, bone marrow derived dendritic cells produced significantly higher levels of IL-1 beta, IL-6, IL-12p70, and MIP-1 alpha as compared to their counterparts receiving free imiquimod. These results suggest that encapsulation of TLR ligands within Ac-DEX microparticles results in increased immunostimulation and potentially better protection from disease when used in conjunction with vaccine formulations.
Subject(s)
Adjuvants, Immunologic/administration & dosage , Dextrans/chemistry , Nanoparticles/chemistry , Adjuvants, Immunologic/chemistry , Aminoquinolines/administration & dosage , Aminoquinolines/chemistry , Animals , Cell Line , Cells, Cultured , Dendritic Cells/drug effects , Dendritic Cells/metabolism , Imiquimod , Interleukin-12/metabolism , Interleukin-1beta/metabolism , Interleukin-6/metabolism , Macrophage Activation/drug effects , Mice , Microscopy, Electron, Scanning , Nanoparticles/ultrastructure , Polymerase Chain ReactionABSTRACT
PURPOSE OF REVIEW: The purpose of this article is to summarize the clinical presentations associated with the classification of ocular allergy. This article also serves to summarize recent findings of pathophysiological mechanisms associated with ocular allergy and to highlight recently improved diagnostic methods for ocular allergic inflammation. RECENT FINDINGS: The term allergic conjunctivitis may not sufficiently describe all forms of allergic eye disease, thus a new classification system is desirable, preferably derived from the varied pathophysiological mechanisms operating in the different forms of ocular allergy. Recent published material has further characterized the roles that inflammatory and structural cells have in ocular allergic inflammation. Improved diagnostic methods have also been developed to assess the underlying causes of ocular allergy. SUMMARY: The underlying immune responses of ocular allergies are complex, indicating the critical need to understand the pathophysiology behind these diseases. Extensive research over the past several years has provided valuable insight into understanding the pathophysiology associated with the different forms of allergic conjunctivitis. Further clarification of the mechanisms associated with different forms of ocular allergy is essential for improved methods of classification, diagnosis, and treatment.
Subject(s)
Conjunctivitis, Allergic , Animals , Antigen-Presenting Cells/immunology , Conjunctivitis, Allergic/diagnosis , Conjunctivitis, Allergic/immunology , Conjunctivitis, Allergic/physiopathology , Cytokines/immunology , Cytokines/metabolism , Eye/immunology , Humans , Inflammation Mediators/immunology , Inflammation Mediators/metabolism , Keratoconjunctivitis/immunology , Mast Cells/immunologyABSTRACT
gp49B, an Ig-like receptor, negatively regulates the activity of mast cells and neutrophils through cytoplasmic immunoreceptor tyrosine-based inhibition motifs. To characterize the role of gp49B further in vivo, gp49B-deficient mice were tested in two allergic models. Responses to ragweed (RW) challenge in the lung and conjunctiva were assessed in models of allergic inflammation and during an infection with parasitic larvae of the nematode Ascaris suum. Infiltration by inflammatory cells into the lung during allergic responses was under negative control of the inhibitory receptor gp49B. Furthermore, an increase in conjunctival inflammation with a predominance of eosinophils, neutrophils, and degranulated mast cells was observed in RW-sensitized, gp49B-deficient mice, which had been challenged in the eye, as compared with C57BL/6 wild-type (WT) controls. Finally, an increase in allergic inflammation in the lungs of A. suum-infected, RW-sensitized mice was observed upon RW challenge, as compared with C57BL/6 WT controls. The observed influx of eosinophils into mucus membranes is characteristic of allergic asthma and allergic conjunctivitis and may contribute to airway hyper-responsiveness, airway remodeling, and mucus production. Expression of gp49B was detected on peripheral eosinophils of control mice and on eosinophils from lungs of mice treated with RW, suggesting a role for gp49B on eosinophils in dampening allergic inflammatory responses.
Subject(s)
Eosinophils/immunology , Hypersensitivity/immunology , Inflammation/immunology , Membrane Glycoproteins/immunology , Receptors, Immunologic/immunology , Allergens , Ambrosia , Animals , Ascaris suum/immunology , Ascaris suum/physiology , Bronchial Provocation Tests , Cell Degranulation , Cell Separation , Conjunctivitis, Allergic/immunology , Cytokines/metabolism , Eosinophilia/immunology , Flow Cytometry , Hypersensitivity/parasitology , Immunoglobulin Isotypes/blood , Inflammation/parasitology , Lung/immunology , Lung/parasitology , Lung/pathology , Mast Cells/cytology , Mast Cells/physiology , Mice , Mice, Inbred C57BL , Mice, Knockout , Parasites/immunology , Parasites/physiologyABSTRACT
We have previously demonstrated that protection from allergic inflammation by Ascaris suum infection was characterized by a global increase in interleukin-10 (IL-10) and the development of protective CD4(+)/CD25(+) T cells (L. Schopf, S. Luccioli, V. Bundoc, P. Justice, C. C. Chan, B. J. Wetzel, H. H. Norris, J. F. Urban, Jr., and A. Keane-Myers, Investig. Ophthalmol. Vis. Sci. 46:2772-2780, 2005). Here, we used A. suum pseudocoelomic fluid (PCF) in lieu of infection to define molecular mechanisms of allergic protection in a mouse model of allergic inflammation. Mice were sensitized with ragweed (RW) and PCF (RW/PCF), PCF alone, or RW alone and then challenged intratracheally, intranasally, and supraocularly with RW. Histological examination of the eyes and lungs, analysis of the bronchoalveolar lavage fluid (BALF), and characterization of ex vivo cytokine responses were performed to determine allergic inflammatory responses. RW/PCF-treated mice had suppressed allergic immune responses compared to mice given RW alone. To investigate whether IL-10 was involved in PCF-mediated allergic protection, similar experiments were performed using mice genetically deficient for IL-10. Persistent protection from allergic disease was observed in the absence of IL-10, indicating the primary mechanism of PCF protection is IL-10 independent. Ex vivo and in vitro analysis of PCF-treated dendritic cells (DC) demonstrated reduced activation receptor expression and cytokine production in response to either RW or lipopolysaccharide stimulation. These findings extend previous studies that showed infection with A. suum alters expression of allergic disease and suggest that PCF can contribute to this effect by interference with DC function.
Subject(s)
Ascaris suum/immunology , Asthma/prevention & control , Conjunctivitis, Allergic/prevention & control , Dendritic Cells/immunology , Interleukin-10/physiology , Respiratory Hypersensitivity/prevention & control , Ambrosia/immunology , Animals , Antigens, Plant/immunology , Asthma/pathology , Bronchoalveolar Lavage Fluid/immunology , Conjunctivitis, Allergic/pathology , Cytokines/metabolism , Inflammation/prevention & control , Interleukin-10/genetics , Lipopolysaccharides/immunology , Mice , Mice, Mutant Strains , Pulmonary Eosinophilia/prevention & control , Respiratory Hypersensitivity/pathology , Respiratory Mucosa/immunology , Respiratory Mucosa/pathology , Th2 Cells/immunologyABSTRACT
We report for the first time that IFNG gene expression requires high mobility group (HMG)A1, the architectural transcription factor mediating enhanceosome formation. This finding is supported by our direct studies of T cells isolated from the HMGA1-transgenic mice displaying an up-regulation of IFN-gamma production and of HMGA1-deficient mice exhibited a decreased IFN-gamma induction. In parallel transfection studies in EL4 cells, we observed elevated IFNG gene promoter activity in cells stably over-expressing HMGA1 and a reduction of such activity in cells expressing dominant-negative HMGA1. In vitro binding assays further demonstrated a specific interaction of HMGA1 to defined regions of the IFNG gene proximal promoter.